CPI-1612 |
Inhibitor of EP300, CREBBP
Probe Summary
Selectivity
Potency
In Vivo
Control Compounds
Chemical Information
References
Vendors
Download
Probe Summary
| Targets | Biochemical/Biophysical Potency | Cellular Potency |
|---|---|---|
| EP300 |
|
|
| CREBBP |
|
Inhibitor
50 nM for inhibition of H3K18ac (HCT-116), and proliferation of JEKO-1 (sensitive to CBP/EP300 inhibition)
50 nM
Selectivity
In Cell Selectivity Assessment
Potency Assay Off-Target:
Eurofins Safety44 off-target screening
Selectivity Assessment Description:
Weak activity in a hERG binding assay (IC50 = 10.4 μM) and displayed moderate inhibition of CYP2C8 ( ...
Potency Cellular
In Vitro
EP300
Mode of Action: Inhibitor
Structure-Activity-Relationship data available? Yes
DOI Reference: 10.1021/acsmedchemlett.0c00155
CREBBP
Mode of Action: Inhibitor
Structure-Activity-Relationship data available? Yes
DOI Reference: 10.1021/acsmedchemlett.0c00155
In Vivo Validations
Mice , Dog, Rat
Dose: 1.0 mg/Kg IV, 5.0 mg/Kg PO (M), 0.5 mg/Kg IV, 1.0 mg/Kg PO (D), 1.0 mg/Kg IV, 5.0 mg/Kg PO (R)
Route of delivery:
Intravenous, Oral
Plasma half life:
5.5 (D), 0.98 (M), 1.2 (R) h
Systemic clearance:
0.42 (D), 3.8 (M), 2.6 (R) L/h/kg
Organ of interest (O):
Brain
Target engagement assay:
Compound 17 was administered orally to 18 male CD-1 mice. Plasma, brain, and CSF levels of compound 17 were then determined at multiple time points. See the Supporting Information for experimental details and additional data.
DOI Reference: 10.1021/acsmedchemlett.0c00155
Negative Control Compounds
Compound 16
Chemical Information
| Molecular Formula | C27H26N6O |
| SMILEs | C[C@H](CN[C@@H](C(=O)Nc1ccc(-c2cnn(C)c2)cn1)c1ccccc1)c1ccc(C#N)cc1 |
| InChI | InChI=1S/C27H26N6O/c1-19(21-10-8-20(14-28)9-11-21)15-30-26(22-6-4-3-5-7-22)27(34)32-25-13-12-23(16-29-25)24-17-31-33(2)18-24/h3-13,16-19,26,30H,15H2,1-2H3,(H,29,32,34)/t19-,26-/m1/s1 |
| Molecular weight | 450.22 Da |
| AlogP | 4.426880000000003 |
| HBond acceptors | 7 |
| HBond donors | 2 |
| Atoms | 60 |
Vendors
Note: This is not an exhaustive list and does not indicate endorsement by the portal.